Cargando…
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
BACKGROUND: Increased synthesis of neopterin and degradation of tryptophan to kynurenine, measured as kynurenine/tryptophan ratio (kyn/trp ratio), are considered in vitro markers of interferon beta-1a (IFNβ-1a) activity. The aim of the study was to investigate the dynamic profile of neopterin and ky...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102623/ https://www.ncbi.nlm.nih.gov/pubmed/21501517 http://dx.doi.org/10.1186/1479-5876-9-42 |
_version_ | 1782204396071813120 |
---|---|
author | Durastanti, Valentina Lugaresi, Alessandra Bramanti, Placido Amato, Mariapia Bellantonio, Paolo De Luca, Giovanna Picconi, Orietta Fantozzi, Roberta Locatelli, Laura Solda', Annalisa Sessa, Edoardo Totaro, Rocco Marino, Silvia Zipoli, Valentina Zorzon, Marino Millefiorini, Enrico |
author_facet | Durastanti, Valentina Lugaresi, Alessandra Bramanti, Placido Amato, Mariapia Bellantonio, Paolo De Luca, Giovanna Picconi, Orietta Fantozzi, Roberta Locatelli, Laura Solda', Annalisa Sessa, Edoardo Totaro, Rocco Marino, Silvia Zipoli, Valentina Zorzon, Marino Millefiorini, Enrico |
author_sort | Durastanti, Valentina |
collection | PubMed |
description | BACKGROUND: Increased synthesis of neopterin and degradation of tryptophan to kynurenine, measured as kynurenine/tryptophan ratio (kyn/trp ratio), are considered in vitro markers of interferon beta-1a (IFNβ-1a) activity. The aim of the study was to investigate the dynamic profile of neopterin and kyn/trp ratio in patients with relapsing remitting multiple sclerosis (RRMS) treated with two different doses of IFNβ-1a over a period of 24 months. METHODS: RRMS patients (n = 101) received open-label IFNβ-1a 22 mcg (low dose, LD) or 44 mcg (high dose, HD) subcutaneously (sc), three times weekly for 24 months. Serum measurements of neopterin, kyn/trp ratio and neutralizing antibodies (NAbs) were obtained before treatment (i.e., at baseline) and 48 hours post-injection every 3 months thereafter. Clinical assessments were performed at baseline and every 6 months. Changes in biomarkers over time were compared between LD- and HD-group as well as between patients with/without relapses and with/without NAbs using Analysis of Variance and Mann-Whitney tests. RESULTS: Neopterin (p < 0.001) and kyn/trp ratio (p = 0.0013) values increased over time vs baseline in both treatment groups. Neopterin values were higher (p = 0.046) in the HD-compared to the LD-group at every time point with the exclusion of months 21 and 24 of therapy. Conversely, there were no differences between the two doses groups in the kyn/trp ratio with the exclusion of month 6 of therapy (p < 0.05). Neopterin levels were significantly reduced in NAb-positive patients starting from month 9 of therapy (p < 0.05); the same result was observed for kyn/trp ratio but only at month 9 (p = 0.02). Clinical status did not significantly affect neopterin production and tryptophan degradation. CONCLUSIONS: Although differences in serum markers concentration were found following IFNβ administration the clinical relevance of these findings needs to be confirmed with more detailed studies. |
format | Text |
id | pubmed-3102623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31026232011-05-27 Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients Durastanti, Valentina Lugaresi, Alessandra Bramanti, Placido Amato, Mariapia Bellantonio, Paolo De Luca, Giovanna Picconi, Orietta Fantozzi, Roberta Locatelli, Laura Solda', Annalisa Sessa, Edoardo Totaro, Rocco Marino, Silvia Zipoli, Valentina Zorzon, Marino Millefiorini, Enrico J Transl Med Research BACKGROUND: Increased synthesis of neopterin and degradation of tryptophan to kynurenine, measured as kynurenine/tryptophan ratio (kyn/trp ratio), are considered in vitro markers of interferon beta-1a (IFNβ-1a) activity. The aim of the study was to investigate the dynamic profile of neopterin and kyn/trp ratio in patients with relapsing remitting multiple sclerosis (RRMS) treated with two different doses of IFNβ-1a over a period of 24 months. METHODS: RRMS patients (n = 101) received open-label IFNβ-1a 22 mcg (low dose, LD) or 44 mcg (high dose, HD) subcutaneously (sc), three times weekly for 24 months. Serum measurements of neopterin, kyn/trp ratio and neutralizing antibodies (NAbs) were obtained before treatment (i.e., at baseline) and 48 hours post-injection every 3 months thereafter. Clinical assessments were performed at baseline and every 6 months. Changes in biomarkers over time were compared between LD- and HD-group as well as between patients with/without relapses and with/without NAbs using Analysis of Variance and Mann-Whitney tests. RESULTS: Neopterin (p < 0.001) and kyn/trp ratio (p = 0.0013) values increased over time vs baseline in both treatment groups. Neopterin values were higher (p = 0.046) in the HD-compared to the LD-group at every time point with the exclusion of months 21 and 24 of therapy. Conversely, there were no differences between the two doses groups in the kyn/trp ratio with the exclusion of month 6 of therapy (p < 0.05). Neopterin levels were significantly reduced in NAb-positive patients starting from month 9 of therapy (p < 0.05); the same result was observed for kyn/trp ratio but only at month 9 (p = 0.02). Clinical status did not significantly affect neopterin production and tryptophan degradation. CONCLUSIONS: Although differences in serum markers concentration were found following IFNβ administration the clinical relevance of these findings needs to be confirmed with more detailed studies. BioMed Central 2011-04-18 /pmc/articles/PMC3102623/ /pubmed/21501517 http://dx.doi.org/10.1186/1479-5876-9-42 Text en Copyright ©2011 Durastanti et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Durastanti, Valentina Lugaresi, Alessandra Bramanti, Placido Amato, Mariapia Bellantonio, Paolo De Luca, Giovanna Picconi, Orietta Fantozzi, Roberta Locatelli, Laura Solda', Annalisa Sessa, Edoardo Totaro, Rocco Marino, Silvia Zipoli, Valentina Zorzon, Marino Millefiorini, Enrico Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients |
title | Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients |
title_full | Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients |
title_fullStr | Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients |
title_full_unstemmed | Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients |
title_short | Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients |
title_sort | neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102623/ https://www.ncbi.nlm.nih.gov/pubmed/21501517 http://dx.doi.org/10.1186/1479-5876-9-42 |
work_keys_str_mv | AT durastantivalentina neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT lugaresialessandra neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT bramantiplacido neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT amatomariapia neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT bellantoniopaolo neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT delucagiovanna neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT picconiorietta neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT fantozziroberta neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT locatellilaura neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT soldaannalisa neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT sessaedoardo neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT totarorocco neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT marinosilvia neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT zipolivalentina neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT zorzonmarino neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients AT millefiorinienrico neopterinproductionandtryptophandegradationduring24monthstherapywithinterferonbeta1ainmultiplesclerosispatients |